Objective: To describe the clinical characteristics of 3 community outbreaks of the novel influenza A (H1N1), and to compare the treatment effects of the traditional Chinese medicine with or without Oseltamivir.
Method: The clinical records of 234 patients in 3 community outbreaks of the novel influenza A (H1N1) infection in June (n = 56), August (n = 96) and October (n = 82) of 2009 were analyzed, and the treatment effects of the traditional Chinese medicine with or without Oseltamivir were evaluated.
Results: The baseline characteristics, including age, temperature, indices of blood tests, hepatic and renal functions were distributed evenly between the 2 treatment groups. The overall analysis suggested that there was no significant difference between the 2 treatment groups in the duration of clinical symptoms (P > 0.05), the duration of fever (P > 0.05), and the hospitalization days (P > 0.05). However, an analysis stratified by the temperature (≥ 39°C or < 39°C) suggested that patients treated by the traditional Chinese medicine with Oseltamivir tended to suffer a shorter duration of fever [40.5 (37.3, 42.0) vs 22.0 (10.5, 30.8) hr, P < 0.01) ] in the higher temperature group.
Conclusions: The traditional Chinese medicine was equivalent to oseltamivir in treating patients with the novel influenza A (H1N1) infection with lower temperature (< 39°C). Oseltamivir was effective in shortening the duration of fever in patients with temperature higher than 39°C.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Distinct evolution patterns of influenza viruses and implications for vaccine development.
Innovation (Camb)
January 2025
School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong (HKU), Hong Kong SAR, China.
In conclusion, the distinct evolution patterns of panzootic influenza A(H5Nx) compared to A(H1N1) and A(H3N2) complicate vaccine development. Effective strategies must consider these unique patterns and the impact of pre-existing immunity. Leveraging AI-based methods for optimized antigen design is essential to mitigate the potential impact of emerging antigenically variable strains and will provide valuable insights for developing more effective vaccines to prepare for future pandemics.
View Article and Find Full Text PDFVV-ECMO adjuvant therapy for complicated with H1N1 infection: a case report.
Front Med (Lausanne)
January 2025
Department of Critical Care Medicine, The First Affiliated Hospital of Guangxi Medical University, Guangxi Clinical Research Center for Critical Care Medicine, Guangxi, China.
Background: Leptospirosis is an acute infectious disease that occurs by infection, progresses rapidly, and has a high mortality rate, with an estimated 1.2 million new cases and nearly 59,000 deaths each year. Due to its diverse clinical manifestations, diagnosis is often delayed.
View Article and Find Full Text PDFSafety, reactogenicity, and immunogenicity of Ad26.COV2.S co-administered with a quadrivalent standard-dose or high-dose seasonal influenza vaccine: a non-inferiority randomised controlled trial.
EClinicalMedicine
January 2025
Janssen Research and Development, Beerse, Belgium.
Background: Vaccine co-administration can increase vaccination coverage. We assessed the safety, reactogenicity, and immunogenicity of concomitant administration of Ad26.COV2.
View Article and Find Full Text PDFPrevalence of respiratory viruses in children in Northeast Brazil: The scenario before the COVID-19 pandemic.
IJID Reg
March 2025
Postgraduate Program in Parasitic Biology, Federal University of Sergipe, Sergipe, Brazil.
Objectives: To investigate the prevalence of nine respiratory viruses and their clinical characteristics in children aged up to 5 years old in the state of Sergipe, Northeast of Brazil in the pre-COVID-19 pandemic period.
Methods: Children with suspected influenza virus infection were included in the study. Clinical samples were screened using real-time quantitative polymerase chain reaction for the diagnosis of adenovirus, parainfluenza (PIV)1, PIV2, PIV3, and human metapneumovirus.
Recombinant probiotic Escherichia coli delivers the polymeric protein of swine influenza virus for protection.
Vet Microbiol
January 2025
College of Veterinary Medicine, Jilin Provincial Engineering Research Center of Animal Probiotics, Jilin Provincial Key Laboratory of Animal Microecology and Healthy Breeding, Engineering Research Center of Microecological Vaccines (Drugs) for Major Animal Diseases, Ministry of Education, Jilin Agricultural University, Changchun 130118, China. Electronic address:
Swine influenza virus invades the host through the respiratory mucosa, which severely restricts the development of the pig breeding industry. To construct monomeric and trimeric vaccines, we developed recombinant Escherichia coli Nissle 1917 (EcN) strains that express the receptor binding site (RBS) of the hemagglutinin (HA) antigen from H1N1 swine influenza virus. After the mucosal immunization of mice, we found that probiotics activated CD40 and CD86 in DCs and increased the levels of IL-4 and IFN-γ secretion by T cells.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!